<DOC>
	<DOC>NCT01350973</DOC>
	<brief_summary>The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.</brief_summary>
	<brief_title>Efficacy of TAK-085 in Participants With Hypertriglyceridemia</brief_title>
	<detailed_description>TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)). This is a phase 3, double-blind, randomized study to evaluate the efficacy and safety of TAK-085 compared to EPA-E in participants with hypertriglyceridemia who are undergoing lifestyle modification. The study period is a total of 20 weeks, comprised of an 8- week screening period and 12 weeks of treatment.</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>1. Participants with values of fasting triglyceride level at Visit 2 (Week 4) and Visit 3 (Week 2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference between these 2 values is within 30% of the higher one. 2. Participants with differences between 2 values of fasting Low density lipoprotein cholesterol level measured at Visit 2 (Week 4) and Visit 3 (Week 2) are within 25% of the higher one. 1. Participants who have coronary artery diseases (eg, confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week 8) or participants with a history of revascularization. 2. Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm within 6 months prior to Visit 1 (Week 8). 3. Participants who have a history or complication of a clinically significant hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within 6 months prior to Visit 1 (Week 8). 4. Participants who have been diagnosed with pancreatitis. 5. Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein CII deficiency or type III familial hyperlipidemia. 6. Participants with complication of Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>